Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1079]

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise...

Prof Jonathan Aning, Dr Francesco Soria and Prof Alexandra Masson-Lecomte

Challenges in high-risk NMIBC: Addressing current unmet needs to optimise patient care ( Prof Jonathan Aning, Dr Francesco Soria and Prof Alexandra Masson-Lecomte )

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts...

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam...

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

EAU 2026: Updates in NMIBC

Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra...

EAU 2026: Updates in NMIBC ( Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra Masson-Lecomte )

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab...

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam...

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes...

Dr Jonathan Anker - Mount Sinai Hospital, New York, USA

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer ( Dr Jonathan Anker - Mount Sinai Hospital, New York, USA )

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in...

Dr Taigo Kato - The Univeristy of Osaka, Suita, Japan

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC ( Dr Taigo Kato - The Univeristy of Osaka, Suita, Japan )

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC...

Dr Nicholas Salgia - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival ( Dr Nicholas Salgia - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer ( Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain )

Microplastics found at higher levels in prostate cancer tissue compared to...

Dr Stacy Loeb - NYU Langone Health, New York, NY

Microplastics found at higher levels in prostate cancer tissue compared to benign tissue ( Dr Stacy Loeb - NYU Langone Health, New York, NY )

AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and...

Dr Pooja Ghatalia - Fox Chase Cancer Center, Pennsylvania, USA

AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and predicts metastatic control with ctDNA ( Dr Pooja Ghatalia - Fox Chase Cancer Center, Pennsylvania, USA )

Real-world cardiovascular risks with novel hormonal therapies in advanced...

Dr Dalia Kaakour - University of California, Irvine, USA

Real-world cardiovascular risks with novel hormonal therapies in advanced prostate cancer ( Dr Dalia Kaakour - University of California, Irvine, USA )

Circulating tumour DNA shows high accuracy for monitoring testicular cancer...

Dr Dalia Kaakour - University of California, Irvine, USA

Circulating tumour DNA shows high accuracy for monitoring testicular cancer across all stages ( Dr Dalia Kaakour - University of California, Irvine, USA )

More from ecancer